Published Study Reveals Next Pharmaceuticals' Flavoxine(TM) Reduces Multiple Heart Health Risk Factors Including High Cholesterol

Published: Jun 19, 2008

SALINAS, Calif.--(BUSINESS WIRE)--Next Pharmaceuticals announced today the results of their placebo-controlled, randomized, double-blind clinical trial, which revealed multiple heart health benefits of Flavoxine. The published study concluded that Flavoxine significantly reduced LDL-cholesterol and triglycerides, while it significantly decreased blood pressure and fasting blood glucose. The study also found that Flavoxine increased HDL-cholesterol (good cholesterol), and may be helpful in weight reduction, as the overweight individuals in the study lost an average of 5% of their body weight in 8 weeks.

Back to news